Company intelligence / Profile preview

Renew Medical

Provo, Utah, United States

Ownership: Private
Development stage: Other

Overview

Renew Biotechnologies has developed proprietary next-generation sequencing platforms for early detection of neurodegenerative diseases and other indications. Their technology enables unbiased epigenetic discovery and high-throughput testing. Current clinical results include ongoing longitudinal studies with academic partners to validate blood-based biomarkers for early diagnosis of Alzheimer’s, Parkinson’s, and ALS. They have won industry awards for innovation but do not yet have commercial diagnostic products widely available.

Therapeutic areas: Infectious DiseasesNeurologyWomen's Health
Modalities: DeviceGenomic toolsEpigenomic tools
Industry: Molecular Diagnostics

Partnerships

Brigham Young UniversityUniversity of Kansas Alzheimer Disease Research Center

Beyond the preview

Go deeper on Renew Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renew Medical.

Explore the full profile